Microbot Medical Inc. has achieved commercial adoption of its LIBERTY Endovascular Robotic System by multiple accounts, including two that participated in the ACCESS-PVI pivotal clinical trial. This adoption follows the system's full market release and is supported by updated medical guidelines promoting reduced radiation exposure and better ergonomics. The company plans to boost its global presence at the upcoming GEST conference in New York and expand international sales with a new VP of Sales for EMEA. These steps aim to grow Microbot's footprint in endovascular robotic technology and improve interventional care worldwide.
Johnson & Johnson has reached a historic $5.5 billion settlement to resolve claims from about 70,000 women and families alleging its talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and meso...
Catalyst Acquisition Corp. announced the pricing of its initial public offering (IPO) at $10 per unit, raising $200 million by offering 20 million units. The units, each including one Class A ordinary share and a partial share right, will begin tradi...
Century Aluminum Company announced it will report its second quarter 2026 earnings on August 6, 2026, after the market closes. The company will also host a live conference call at 5:00 p.m. Eastern time the same day, accessible via its website. This ...
Kelso Technologies posted a 28% revenue increase in Q2 2026 to $2.25 million, signaling recovery from a weak start to the year despite a challenging industry environment with declining tank car deliveries. The company is actively reducing costs and p...
BitMEX, a pioneering crypto exchange known for 100x leverage perpetual swaps, and BitMart, once a top 10 exchange, have both announced shutdowns after years of operation. Unlike the FTX collapse, BitMEX's closure is orderly without insolvency, though...
